Mankind Pharma surges on acquiring `Rivotril` brand from Roche for Indian market
Mankind Pharma is currently trading at Rs. 2117.50, up by 50.05 points or 2.42% from its previous closing of Rs. 2067.45 on the BSE.
The scrip opened at Rs. 2060.60 and has touched a high and low of Rs. 2129.50 and Rs. 2056.20 respectively. So far 5023 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2726.75 on 15-Jul-2025 and a 52 week low of Rs. 2014.85 on 23-Feb-2026.
Last one week high and low of the scrip stood at Rs. 2243.00 and Rs. 2056.00 respectively. The current market cap of the company is Rs. 87437.04 crore.
The promoters holding in the company stood at 72.66%, while Institutions and Non-Institutions held 24.55% and 2.79% respectively.
Mankind Pharma has acquired the brand ‘Rivotril’ from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. Often regarded as a Textbook brand in its category with a strong clinical legacy, Rivotril further strengthens the company’s presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio.
The acquisition builds on the company’s growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company’s overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders. Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
